1-anilino-8-naphthalenesulfonate has been researched along with Menopause in 16 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sixty-eight women in pre-menopause (PMW) and 216 in post-menopause (POMW) were recruited; eighty-three had undergone HRT for at least 12 months, where 48 received conjugated estrogens alone (EHRT) and 35 received conjugated estrogen and medroxyprogesterone acetate (CHRT)." | 3.77 | Post-menopausal hormone therapy reduces autoantibodies to oxidized apolipoprotein B100. ( Castanho, VS; de Faria, EC; Gidlund, M; Nakamura, R, 2011) |
| " It is not known whether this type of HDL2 reduction is accompanied by increased atherogenesis but as long as the issue is unresolved some caution is needed in the long-term use of levonorgestrel, particularly in women who simultaneously are given some other drug depressing plasma HDL2 concentration." | 1.26 | Reduction of plasma high-density lipoprotein cholesterol and increase of postheparin plasma hepatic lipase activity during progestin treatment. ( Kuusi, T; Nikkilä, EA; Sipinen, S; Tikkanen, MJ, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (50.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JE | 1 |
| Kim, EJ | 1 |
| Kim, MH | 1 |
| Hong, J | 1 |
| Yang, WM | 1 |
| Hiraki, E | 1 |
| Furuta, S | 1 |
| Kuwahara, R | 1 |
| Takemoto, N | 1 |
| Nagata, T | 1 |
| Akasaka, T | 1 |
| Shirouchi, B | 1 |
| Sato, M | 1 |
| Ohnuki, K | 1 |
| Shimizu, K | 1 |
| Castanho, VS | 1 |
| Gidlund, M | 1 |
| Nakamura, R | 1 |
| de Faria, EC | 1 |
| Chamberlain, AM | 1 |
| Folsom, AR | 1 |
| Schreiner, PJ | 1 |
| Boerwinkle, E | 1 |
| Ballantyne, CM | 1 |
| Schaefer, EJ | 1 |
| Foster, DM | 2 |
| Zech, LA | 1 |
| Lindgren, FT | 1 |
| Brewer, HB | 1 |
| Levy, RI | 1 |
| Hazzard, WR | 4 |
| Haffner, SM | 1 |
| Kushwaha, RS | 1 |
| Applebaum-Bowden, D | 4 |
| Tikkanen, MJ | 2 |
| Nikkilä, EA | 2 |
| Kuusi, T | 2 |
| Sipinen, S | 1 |
| Taggart, HM | 1 |
| Haffner, S | 1 |
| Warnick, GR | 2 |
| Cheung, MC | 1 |
| Albers, JJ | 3 |
| Chestnut, CH | 1 |
| Grandjean, PW | 1 |
| Crouse, SF | 1 |
| O'Brien, BC | 1 |
| Rohack, JJ | 1 |
| Brown, JA | 1 |
| Murdoch, SJ | 1 |
| Carr, MC | 1 |
| Hokanson, JE | 1 |
| Brunzell, JD | 1 |
| Glueck, CJ | 2 |
| Fallat, RW | 1 |
| Scheel, D | 2 |
| Vartiainen, E | 1 |
| Basdevant, A | 1 |
| de Lignieres, B | 1 |
| Simon, P | 1 |
| Blache, D | 1 |
| Ponsin, G | 1 |
| Guy-Grand, B | 1 |
| Colvin, PL | 1 |
| Auerbach, BJ | 1 |
| Case, LD | 1 |
| McLean, P | 1 |
| Steinmetz, A | 1 |
| Fontana, D | 1 |
| Matthys, C | 1 |
| Cheung, M | 1 |
| Fishback, J | 1 |
| Steiner, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia[NCT00005313] | 450 participants (Actual) | Observational | 2001-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 1-anilino-8-naphthalenesulfonate and Menopause
| Article | Year |
|---|---|
The effects of menopausal status and exercise training on serum lipids and the activities of intravascular enzymes related to lipid transport.
Topics: Adult; Analysis of Variance; Apolipoproteins; Biological Transport; Endothelium, Vascular; Female; H | 1998 |
15 other studies available for 1-anilino-8-naphthalenesulfonate and Menopause
| Article | Year |
|---|---|
Polygonatum stenophyllum improves menopausal obesity via regulation of lipolysis-related enzymes.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Obesity Agents; Diet, High-Fat; Female; Lipase; Lipolysis; | 2016 |
Anti-obesity activity of Yamabushitake (Hericium erinaceus) powder in ovariectomized mice, and its potentially active compounds.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Basidiomycota; Biological Products; Cholesterol; Diet; | 2017 |
Post-menopausal hormone therapy reduces autoantibodies to oxidized apolipoprotein B100.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Autoantibodies; Autoimmune Diseases; Cardiovas | 2011 |
Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Alleles; Apolipoproteins E; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; | 2008 |
The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Cholesterol; Ethinyl Estradiol; Femal | 1983 |
Preliminary report: kinetic studies on the modulation of high-density lipoprotein, apolipoprotein, and subfraction metabolism by sex steroids in a postmenopausal woman.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol | 1984 |
Reduction of plasma high-density lipoprotein cholesterol and increase of postheparin plasma hepatic lipase activity during progestin treatment.
Topics: Cholesterol; Cholesterol, HDL; Female; Heparin; Humans; Levonorgestrel; Lipase; Lipoproteins, HDL; L | 1981 |
Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis.
Topics: Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Cholesterol; Cholesterol, HDL; Chole | 1982 |
PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance.
Topics: Adipose Tissue; Adult; Blood Glucose; Carrier Proteins; Cohort Studies; Female; Humans; Insulin; Ins | 2000 |
Effects of estrogenic compounds on triglyceride kinetics.
Topics: Blood Protein Electrophoresis; Cholesterol; Estrogens, Conjugated (USP); Female; Glycerol; Half-Life | 1975 |
Treatment of post-menopausal hypercholesterolaemia with estradiol.
Topics: Adult; Estradiol; Female; Humans; Hypercholesterolemia; Lipase; Lipoproteins, HDL; Lipoproteins, LDL | 1979 |
Hepatic lipase activity during oral and parenteral 17 beta-estradiol replacement therapy: high-density lipoprotein increase may not be antiatherogenic.
Topics: Administration, Cutaneous; Administration, Oral; Analysis of Variance; Apolipoproteins; Arterioscler | 1991 |
A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women.
Topics: Cholesterol, HDL; Dose-Response Relationship, Drug; Estradiol; Female; Humans; Lipase; Liver; Menopa | 1991 |
Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women.
Topics: Aged; Apolipoproteins; Ethinyl Estradiol; Female; Humans; Lipase; Lipids; Lipoproteins; Menopause; M | 1989 |
Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia.
Topics: Aged; Blood Glucose; Estrogens; Female; Heparin; Humans; Hyperlipidemias; Lipase; Lipoproteins; Male | 1972 |